ArticleSpringerPlus2015

Patients' preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments.

Surachat Ngorsuraches et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.